The Institute for Clinical and Economic Review (ICER) has released the official procedures for conducting its sixth assessment of major drugs that experienced substantial price increases without adequate evidence to justify the increases. The drug pricing watchdog will identify 10 drugs with net price hikes that have generated the largest increase in drug spending at the federal level and is seeking public input for an additional three drugs that have experienced similar price increases over the same timeframe but won’t...